Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Axonemal dynein light chain domain-containing protein 1 (AXDND1) is a protein-coding gene primarily expressed in the testis and is essential for spermiogenesis and male fertility in mammals[1][2][7]. It is predicted to function in regulating manchette dynamics, spermatid head shaping, and assembly of the sperm flagellum, likely by participating in protein and vesicle transport along microtubules[1][2]. Disruption of AXDND1 in mouse models leads to male sterility, abnormal sperm structures, and defective sperm motility, with similar pathogenic variants associated with human azoospermia[2]. The gene contains a conserved dynein light chain domain but is significantly larger than canonical dynein light chain proteins, and is considered an atypical member of the dynein-related protein family[2]. There is currently no evidence indicating it is targeted by existing drugs or used as a biomarker in clinical settings[1][2][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Axonemal dynein light chain domain-containing protein 1 (AXDND1).